Relationship between exhaled markers and airway pathology in smokers with and without airflow obstructio
Completed
- Conditions
- chronic bronchitis10006436emphysema
- Registration Number
- NL-OMON34947
- Lead Sponsor
- eids Universitair Medisch Centrum
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Completed
- Sex
- Not specified
- Target Recruitment
- 24
Inclusion Criteria
- Male or female subject, age > 40 years, current or ex-smokers
- Plannend lung resection for primary lung cancer of any size.
- COPD: irreversible airflow limitation (postbronchodilator FEV1/FVC < 70% according to GOLD guidelines).
- non-COPD: FEV1/FVC >70%
-Written informed consent.
Exclusion Criteria
-Patients with a history of asthma or other active lung disease.
-Lung resection for other reasons than lung cancer (e.g. infective diseases like bronchiectasis).
Study & Design
- Study Type
- Observational non invasive
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method <p>To demonstrate that the change in slope of the sbN2-test (phase III/IV) is<br /><br>correlated to an influx of inflammatory cells in the small airways (histology,<br /><br>morphology, immunopathology) and to inflammatory markers in exhaled breath in<br /><br>patients with normal and abnormal small airways function.</p><br>
- Secondary Outcome Measures
Name Time Method <p>To demonstrate that the presence of lung cancer per se is a condition leading<br /><br>to a change in the breath pattern. Exhaled breath patterns will be assessed by<br /><br>the eNose and the differential mobility spectrometry before and after lung<br /><br>cancer surgery.<br /><br><br /><br>To assess whether there is a difference in expression of macrophage Mf1 and Mf2<br /><br>markers, and in mast cell subsets (chymase/tryptase positive vs. tryptase<br /><br>positive) in small and large airways from patients with COPD at lung tissue<br /><br>level.<br /><br><br /><br>Furthermore we are interested whether there is a relationship between the<br /><br>expression of the 1,25(OH)2D3 degrading enzyme CYP24A1 and antimicrobial<br /><br>peptides in small and large airways in COPD patients and whether there is a<br /><br>correlation with local inflammation and lung function. </p><br>